What is the risk of rebleeding in a 30-year-old patient with upper gastrointestinal (GI) bleeding from nonsteroidal anti-inflammatory drug (NSAID) abuse, with an endoscopy showing an adherent clot, stable vital signs, and no comorbidities?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The risk of rebleeding in this 30-year-old patient with upper GI bleeding from NSAID abuse, an adherent clot on endoscopy, stable vital signs, and no comorbidities is moderate, approximately 20-30%. This patient should immediately discontinue all NSAIDs and receive high-dose proton pump inhibitor (PPI) therapy, such as esomeprazole 40mg or pantoprazole 40mg twice daily for 72 hours intravenously, followed by once-daily oral PPI for 4-8 weeks, as recommended by the most recent guidelines 1.

Key Considerations

  • The presence of an adherent clot on endoscopy represents a Forrest class IIb lesion, which carries a significant rebleeding risk, as highlighted in studies 1.
  • The patient's young age and absence of comorbidities are favorable prognostic factors, but NSAID-induced ulcers can be aggressive.
  • Endoscopic therapy with clot removal followed by treatment of the underlying lesion is recommended to further reduce rebleeding risk, as suggested by the guidelines 1.
  • The patient should be monitored for at least 24-48 hours with serial hemoglobin measurements and vital sign checks.

Management Plan

  • Discontinue all NSAIDs immediately.
  • Initiate high-dose PPI therapy as soon as possible, as recommended by the guidelines 1.
  • Perform endoscopic therapy with clot removal and treatment of the underlying lesion.
  • Monitor the patient closely for signs of rebleeding.
  • Test for H. pylori after the acute phase and prescribe eradication therapy if positive, as recommended by the guidelines 1.
  • Long-term, the patient should avoid NSAIDs completely or use COX-2 selective inhibitors with gastroprotection if absolutely necessary for pain management.

From the Research

Patient's Condition and Risk Assessment

  • The patient is 30 years old with upper GI bleeding from NSAID abuse, and endoscopy showed an adherent clot.
  • The patient has stable vital signs and no comorbidities.
  • The Rockall score is used to assess the risk of rebleeding and mortality in patients with upper GI bleeding.

Rockall Score and Its Applicability

  • The Rockall score is predictive of rebleeding and mortality in patients with variceal hemorrhage and peptic ulcers 2.
  • The score can be used in patients undergoing therapeutic endoscopy for upper GI bleeding to identify those with high risk for mortality 3.
  • The post-endoscopy Rockall score is associated with rebleeding and mortality in patients with non-varicose UGIB 4.

Patient's Rockall Score and Risk of Rebleeding

  • The patient's Rockall score is 2, which indicates a moderate risk of rebleeding.
  • The Forest score is also relevant in this case, with a score of 2 for an adherent clot.
  • The patient has an increased risk of rebleeding due to the presence of an adherent clot and NSAID abuse 5, 6.

Treatment and Management

  • The use of proton pump inhibitors (PPIs) may reduce the risk of rebleeding in patients with upper GI bleeding 6.
  • The patient may require PPIs to reduce the risk of rebleeding, but the optimal dose and duration of treatment need to be established 6.
  • The role of prostaglandins in preventing NSAID-induced gastrointestinal injury is well established, but their use in this patient is not clearly indicated 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Applicability of the Rockall score in patients undergoing endoscopic therapy for upper gastrointestinal bleeding.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.